This leads to fatigue, reduced calorie burn, and weight gain, often around the midsection
The 2024 SURMOUNT-5 head-to-head trial demonstrated Zepbound's clinical superiority over Wegovy by a meaningful margin (47% greater relative weight loss)
The latest GLP-1 drug approved for weight loss, tirzepatide, sold as Zepbound, appears to beat out semaglutide with nearly 19 percent of body weight lost, over 40 pounds (18 kg), with more like five and a half inches (14 cm) off the waist
Blockade of Autophagy Prevents the Progression of Hyperuricemic Nephropathy Through Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis
While semaglutide was originally prescribed to treat type 2 diabetes, its now used to combat obesity and help patients manage blood sugar, regulate metabolism, lower blood pressure, and minimize the risk of cardiovascular disease and other weight-related health concerns